RecruitingPlatinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).

Sponsor: Context Therapeutics Inc.

You may qualify if…

✓ Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer.
✓ Participants with measurable disease per RECIST 1.1.
✓ ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.
✓ Participants with adequate organ function.

You may not qualify if…

✕ Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.
✕ Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.
✕ Concurrent participation in another investigational clinical trial.